Cargando…

Molecular mechanisms of resistance to HER2-targeted therapy

Detalles Bibliográficos
Autor principal:	Esteva, FJ
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284886/ http://dx.doi.org/10.1186/bcr2283

Ejemplares similares

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Update on HER2-directed therapy
por: Slamon, D
Publicado: (2005)

Adjuvant therapy of HER2(+ )breast cancer
por: Winer, EP
Publicado: (2009)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer
por: Gijsen, M, et al.
Publicado: (2010)

Abdominal and pelvic complications of molecular targeted therapy
por: Gore, Richard M, et al.
Publicado: (2014)

Role of HER2 in local relapse and metastasis
por: Ménard, S
Publicado: (2005)

Herceptin-sensitivity of HER2-transgenic mouse mammary tumors
por: Schwall, RH, et al.
Publicado: (2003)

O028 Combination Pharmacological Therapy Targeting Multiple Mechanisms of Sleep Apnea
por: Sands, S, et al.
Publicado: (2022)

Differentiation therapy: targeting breast cancer stem cells to reduce resistance to radiotherapy and chemotherapy
por: Roy, R, et al.
Publicado: (2010)

The molecular mechanisms underlying diabetic complications
por: Chiarelli, Francesco, et al.
Publicado: (2013)

Molecular mechanisms of normal and pathological aging
por: López-Otín, Carlos
Publicado: (2015)

P008 Molecular mechanisms associated with fluconazole resistance and genetic diversity in clinical Candida krusei isolates from North India
por: Jain, Kusum, et al.
Publicado: (2022)

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer
por: Cortés-Funes, H, et al.
Publicado: (2009)

Use of the anti HER-2/neu antibody Herceptin in the treatment of human breast cancer: biological rationale and clinical results
por: Slamon, DJ
Publicado: (2000)

Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.
por: Ahmed, Nabil, et al.
Publicado: (2015)

Molecular mechanisms for simvastatin-mediated enhancement of synaptic plasticity
por: Mans, Robert A, et al.
Publicado: (2012)

Gene amplification in breast cancer – looking for the molecular mechanisms
por: Kovalenko, Sergei
Publicado: (2010)

Cytokine induced molecular mechanisms of bone/cartilage metabolism
por: Schett, Georg
Publicado: (2011)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Microbicide development: multiple targets, multiple mechanisms
por: Shattock, Robin
Publicado: (2006)

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial
por: Rodenhuis, S, et al.
Publicado: (2005)

Molecular dissection of an adaptive epigenetic memory mechanism in norway spruce
por: Yakovlev, Igor, et al.
Publicado: (2011)

Molecular bioactivity extrapolation to novel targets by support vector machines
por: Van Westen, Gerard JP, et al.
Publicado: (2010)

TP53 and additional pathways in therapy resistance
por: Lønning, PE
Publicado: (2005)

Targeting new therapies in combination with hormonal therapies for ER-positive breast cancer
por: Dowsett, M
Publicado: (2005)

Controversial Issue Session: Brace treatment in infantile scoliosis: brace treatment problems
por: Sánchez Pérez-Grueso, FJ
Publicado: (2012)

Molecular mechanism of unloading-mediated muscle atrophy and development of its countermeasures
por: Nikawa, Takeshi
Publicado: (2012)

Quantum-mechanics-based molecular interaction fields for 3D-QSAR
por: ElKerdawy, Ahmed, et al.
Publicado: (2014)

Envisioning new targets and new approaches for molecular-based cancer therapeutics
por: Tainer, JA
Publicado: (2005)

Novel resistance mechanism of HIV-1 To peptide fusion inhibitors
por: Gupta, Nidhi, et al.
Publicado: (2006)

International perspectives on adherence and resistance to HIV antiretroviral therapy
por: Bangsberg, D
Publicado: (2010)

Predicting response/resistance to endocrine therapy for breast cancer
por: Miller, WR, et al.
Publicado: (2005)

Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer
por: Baselga, J, et al.
Publicado: (2011)

Mechanism of effective orthotic therapy for the painful cavus foot
por: Najafi, Bijan, et al.
Publicado: (2013)

The EGF receptor family as targets for breast cancer therapy
por: Baselga, J
Publicado: (2000)

Targeting the cell cycle for prognosis and therapy of breast cancer
por: Keyomarsi, K, et al.
Publicado: (2005)

Molecular targets for PDE inhibitor-mediated improvement of cardiac dysfunction in the mdx mouse?
por: Adamo, Candace M, et al.
Publicado: (2011)

P017 Echinocandin resistance mechanism in Candida tropicalis and Candida glabrata
por: Sharma, Dipti, et al.
Publicado: (2022)

Tumour-selective transcriptional targeting for breast cancer gene therapy
por: Hurst, HC
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_85kdh8vggki9fs2lftfok3mrg7